Surface-engineered nanoliposomes by chelating ligands for modulating the neurotoxicity associated with β-amyloid aggregates of Alzheimer's disease.

Pharmaceutical Research
Maluta S MufamadiViness Pillay

Abstract

To develop chelating ligand-bound nanoliposomes (NLPs) for the prevention and reversal of β-Amyloid (Aβ) aggregation associated with promoting neurotoxicity in Alzheimer disease (AD). Four different chelating ligands (CuAc, EDTA, histidine and ZnAc) were surface-engineered onto NLPs using either covalent or non-covalent conjugation. Successful conjugation of chelating ligands onto the surface of NLPs was confirmed by characterization studies: SEM, TEM and FTIR analysis. Chelation energetics of EDTA with Cu(II)/Zn(II)-Aβ(10-21) and nanoformation of emulsified polymers were computed and corroborated with experimental and analytical data using chemometric molecular modeling. The modified NLPs produced were spherical in shape, 127-178 nm in size, with polydispersity index from 0.217-0.920 and zeta potential range of -9.59 to -37.3 mV. Conjugation efficiencies were 30-76 %, which confirmed that chelating ligands were attached to the NLP surface. In vitro and ex vivo results elucidated the effectiveness of chelating ligand-bound NLPs for prevention of CuAβ(1-42) or ZnAβ(1-42) aggregate buildup associated with neurotoxicity in PC12 neuronal cells, as well as promotion of intracellular uptake in the presence of Cu(II) or Zn(II) metal i...Continue Reading

References

Jul 1, 1976·Proceedings of the National Academy of Sciences of the United States of America·L A Greene, A S Tischler
Oct 1, 1995·The Biochemical Journal·L L IversenM S Shearman
Jul 17, 1998·Journal of the Neurological Sciences·M A LovellW R Markesbery
Aug 24, 1999·Pediatrics International : Official Journal of the Japan Pediatric Society·N ShimizuT Aoki
Aug 3, 2001·Nature Reviews. Neuroscience·D H SmallJ C Bornstein
Mar 29, 2002·Analytical Sciences : the International Journal of the Japan Society for Analytical Chemistry·Tamio KamidateAkihiko Ishida
Oct 23, 2002·Journal of Neuroscience Research·Martin Citron
Oct 24, 2002·Journal of the American Chemical Society·David M MorganDavid G Lynn
Dec 10, 2002·Neurobiology of Aging·Ashley I Bush
Mar 5, 2003·International Journal of Pharmaceutics·A P C A JanssenG Molema
May 20, 2003·International Journal of Pharmaceutics·D D VermaA Fahr
Jul 2, 2004·The New England Journal of Medicine·Jeffrey L Cummings
Aug 31, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Fernanda G De FeliceSérgio T Ferreira
Jan 22, 2005·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Zhengrong CuiRussell J Mumper
Feb 18, 2005·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Anita Schnyder, Jörg Huwyler
May 6, 2005·The Journal of Laboratory and Clinical Medicine·Matilde MarcelliniValerio Nobili
Nov 3, 2005·BMC Cardiovascular Disorders·Dugald M R SeelyEdward J Mills
Mar 15, 2006·International Journal of Pharmaceutics·N Popovic, P Brundin
Nov 23, 2006·Journal of Controlled Release : Official Journal of the Controlled Release Society·Ryo SuzukiKazuo Maruyama
May 15, 2007·Colloids and Surfaces. B, Biointerfaces·Junmin ZhuRoger E Marchant
Jul 17, 2007·Biometals : an International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine·Daxiong HanPin Yang
Dec 11, 2007·Neurobiology of Aging·Dorothea StrozykAshley I Bush
Jul 16, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Ashley I Bush, Rudolph E Tanzi
Jun 23, 2009·Trends in Pharmacological Sciences·Paolo ZattaStefano L Sensi
Jul 1, 2009·Acta Pharmaceutica : a Quarterly Journal of Croatian Pharmaceutical Society and Slovenian Pharmaceutical Society, Dealing with All Branches of Pharmacy and Allied Sciences·Fatemeh AtyabiRassoul Dinarvand
Aug 27, 2009·Langmuir : the ACS Journal of Surfaces and Colloids·Monica M Lozano, Marjorie L Longo
Sep 3, 2009·Toxicology Letters·Leshuai W ZhangNancy A Monteiro-Riviere
Oct 6, 2009·Journal of Controlled Release : Official Journal of the Controlled Release Society·Xue YingQiang Zhang
Nov 7, 2009·Recent Patents on CNS Drug Discovery·Rosanna Squitti, Giancarlo Zito
Jan 27, 2010·The Mount Sinai Journal of Medicine, New York·Alex L Lublin, Sam Gandy
Feb 12, 2010·Annals of the New York Academy of Sciences·Girish ModiYahya E Choonara
Feb 19, 2010·Journal of Alzheimer's Disease : JAD·Nanditha G NairV Prakash Reddy
May 7, 2010·Progress in Neurobiology·James A Duce, Ashley I Bush
Jul 20, 2010·Interdisciplinary Sciences, Computational Life Sciences·T MarinoM Pavelka
Jan 25, 2011·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Ron BrookmeyerWalter A Kukull
Jun 15, 2011·Colloids and Surfaces. B, Biointerfaces·Yahya E ChoonaraDebbie-Leigh Jarvis

❮ Previous
Next ❯

Citations

Mar 29, 2013·International Journal of Pharmaceutics·Maluta S MufamadiViness Pillay
May 2, 2015·Nanomedicine·Maria GregoriSimona Mancini
Aug 9, 2018·Nanomedicine·Weiyuan ZhangZhiyong He
Jan 30, 2018·Journal of Cellular and Molecular Medicine·Olufemi D AkiloViness Pillay

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.